This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Ophthalmology Podcasts

The Macular Minute Episode 12

with Hani Hasan, Rossella Anzidei and Richard Gale

The Macular Minute Banner

Drying Effects of EYLEA® (aflibercept) 8 mg

In this

4-minute
episode, we are joined by a panel of three consultant ophthalmologists to talk about their experience with the
drying effects of EYLEA 8 mg
.

 

This promotional podcast series has been organised and funded by Bayer and is for UK healthcare professionals only.

Prescribing information for EYLEA® (aflibercept) 8 mg

can be found here
.

Prescribing information for EYLEA® (aflibercept) 2 mg

can be found here
.

Speakers & Disclosures

Hani Hasan

Consultant Ophthalmologist at Newcastle upon Tyne Hospitals NHS Foundation Trust

Speaker Disclosures:
Speaker and travel grants: AbbVie, Bayer and Roche

 

Rossella Anzidei

Consultant Ophthalmologist at University Hospitals Leicester NHS Trust

Speaker Disclosures:
Speaker and travel grants: AbbVie, Bayer and Novartis

 

Richard Gale

Professor of Ophthalmology at York University and Honorary Consultant Ophthalmologist at Scarborough Teaching Hospitals NHS Foundation Trust

Speaker Disclosures:
Speaker and travel grants: AbbVie, Alimera Sciences, Allergan, Amgen, Bayer, Biogen, Boehringer Ingelheim, Gilead Sciences, Heidelberg Pharma, Lux Biosciences, Notal Vision, Novartis, Roche, Santen

References

  1. PULSAR clinical trial: Lanzetta P et al. Lancet 2024; 403 (10432): 1141-1152.
  2. EYLEA® 40 mg/mL Summary of Product Characteristics.
  3. EYLEA® 114.3 mg/mL Summary of Product Characteristics.
EYLEA® (aflibercept) 8 mg
Discover data and resources about EYLEA 8 mg
PP-EYL-GB-2911, July 2025
The Macular Minute: Podcast Series
Your source for quick expert insights in medical retina
PP-EYL-GB-2538, January 2025
EYLEA® (aflibercept) 2 mg
Discover data and resources about EYLEA 2 mg
PP-EYL-GB-2793, March 2025

PP-EYL-GB-2552 | December 2024